✦ LIBER ✦

Bortezomib in recurrent and/or refractory multiple myeloma : Initial clinical experience in patients with impaired renal function

✍ Scribed by Sundar Jagannath; Bart Barlogie; James R. Berenson; Seema Singhal; Raymond Alexanian; Gordan Srkalovic; Robert Z. Orlowski; Paul G. Richardson; Jessica Anderson; Darrell Nix; Dixie L. Esseltine; Kenneth C. Anderson

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 137 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20888

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Retreatment with bortezomib alone or in

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

✍ Raman Sood; Harry Carloss; Robert Kerr; Jose Lopez; Martin Lee; Mark Druck; Ian 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I